Topical co-enzyme Q10 formulations and methods of use
Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.
1. A method of treating squamous cell carcinoma in a subject, comprising topically administering to the subject a composition comprising 1% to 15% w/w of Coenzyme Q10, in an amount effective and for a sufficient time and frequency to reduce growth of the squamous cell carcinoma in the subject.
2. The method of claim 1 , wherein the subject is human.
3. The method of claim 1 or 2 , wherein the composition comprising Coenzyme Q10 is formulated as a topical cream and/or a topical liposomal formulation.
4. The method of claim 1 or 2 , wherein the composition comprises 1% to 10% w/w of Coenzyme Q10.
5. The method of claim 1 or 2 , wherein the composition comprises 1% to 5% w/w of Coenzyme Q10.
6. The method of claim 1 or 2 , wherein the composition comprising Coenzyme Q10 is administered with an additional anti-cancer agent.
7. The method of claim 6 , wherein the additional anti-cancer agent is a chemotherapeutic agent and/or an anti-angiogenic agent.
8. The method of claim 7 , wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, taxanes, busulfan, methotrexate, daunorubicin, doxorubicin, melphalan, cladribine, vincristine, vinblastine, chlorambucil, tamoxifen, taxol, camptothecin, actinomycin-D, mitomycin C, combretastatin, cisplatin, etoposide, verapamil, podophyllotoxin, and 5-fluorouracil.
9. The method of claim 6 , wherein administration of the additional anti-cancer agent to the subject comprises
administration of the composition comprising Coenzyme Q10 prior to administration of the additional anti-cancer agent.
10. The method of claim 6 , wherein administration of the additional anti-cancer agent to the subject comprises:
a) co-administration of the composition comprising Coenzyme Q10 with the additional anti-cancer agent; or
b) administration of the composition comprising Coenzyme Q10 after the additional anti-cancer agent.